跳至主要内容
临床试验/NCT00445094
NCT00445094已完成4 期

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit

Merck Sharp & Dohme LLC0 个研究点目标入组 120 人开始时间: 2006年11月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
120
主要终点
A 30-day-survival rate in the intensive care unit evaluated by Acute Physiology and Chronic Health (APACH II) Disease Classification System II score

研究概览

简要总结

The primary objective of this study is a comparison between MK0787B and standard therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Greater than 18 years of age
  • Patient is diagnosed with nosocomial pneumonia

排除标准

  • Immunological deficient patients
  • Pregnant women and nursing mothers
  • A fungus is identified before the study enrollment
  • Received vancomycin or imipenem for more than 5 days before icu admission

结局指标

主要结局

A 30-day-survival rate in the intensive care unit evaluated by Acute Physiology and Chronic Health (APACH II) Disease Classification System II score

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验